Xenon Pharmaceuticals said its treatment for a common type of seizure disorder significantly reduced the frequency of those seizures compared to a placebo.
Xenon Pharmaceuticals said Monday that its treatment for a common type of seizure disorder significantly reduced the frequency of those seizures compared to a placebo — achieving the main goal of a Phase 3 clinical trial.
The new study results also exceeded the treatment effect reported in the company’s previous mid-stage study.
Xenon said it expects to seek the approval of its drug, called azetukalner, with the Food and Drug Administration in the third quarter.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/03/09/xenon-pharmaceuticals-azetukalner-epilepsy-fos/)
